Abstract
There is an urgent need to identify which COVID-19 patients will develop life-threatening illness so that scarce medical resources can be optimally allocated and rapid treatment can be administered early in the disease course, when clinical management is most effective. To aid in the prognostic classification of disease severity, we performed untargeted metabolomics profiling of 341 patients with plasma samples collected at six longitudinal time points. Using the temporal metabolic profiles and machine learning, we then built a predictive model of disease severity. We determined that the levels of 25 metabolites measured at the time of hospital admission successfully predict future disease severity. Through analysis of longitudinal samples, we confirmed that these prognostic markers are directly related to disease progression and that their levels are restored to baseline upon disease recovery. Finally, we validated that these metabolites are also altered in a hamster model of COVID-19. Our results indicate that metabolic changes associated with COVID-19 severity can be effectively used to stratify patients and inform resource allocation during the pandemic.
Competing Interest Statement
The AG-S laboratory has received research support from Pfizer, Pharmamar, Blade Therapeutics, Avimex, Dynavax, Kenall Manufacturing, ImmunityBio, Nanocomposix, Senhwa Biosciences and 7Hills Pharma. AG-S has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7 Hills Pharma, Avimex, Vaxalto, Accurius and Esperovax. G.J.P. is a scientific advisor for Cambridge Isotope Laboratories. All other authors declare no conflicts of interest.
Funding Statement
This work was supported by funding from the National Institutes of Health grants R24OD024624 (G.J.P.) and R35ES2028365 (G.J.P.). This study utilized samples obtained from the Washington University School of Medicine's COVID-19 biorepository, which is supported by: the Barnes-Jewish Hospital Foundation; the Siteman Cancer Center grant P30 CA091842 from the National Cancer Institute of the National Institutes of Health; and the Washington University Institute of Clinical and Translational Sciences grant UL1TR002345 from the National Center for Advancing Translational Sciences of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the view of the NIH. For their work in the development and maintenance of the COVID-19 biorepository, we would like to thank Jane O'Halloran, MD, PhD; Charles Goss, PhD, and Phillip Mudd, MD, PhD. This work was also partly supported by CRIP (Center for Research for Influenza Pathogenesis), a NIAID supported Center of Excellence for Influenza Research and Surveillance (CEIRS, contract HHSN272201400008C; WCL, RAA, and AGS); by NIAID grant U19AI135972; by NCI grant U54CA260560; by supplements to NIAID grants U19AI135972, U19AI142733 and DoD grant W81XWH-20-1-0270; by the Defense Advanced Research Projects Agency (HR0011-19-2-0020); by the generous support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611 (5384); and by anonymous donors (A.G.S.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The human study relevant to Barnes Jewish Hospital, Christian Hospital, and Washington University were reviewed and approved by the Washington University in Saint Louis Institutional Review Board (WU-350 study approval #202003085, and plasma metabolomics study approval #202004204). All animal studies were approved by the Institutional Care and Use Committee at Mount Sinai School of Medicine, following the humane care and use guidelines set by the institution.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The raw LC/MS data as well as the processed metabolic profiles and their corresponding deidentified metadata for the human and animal samples will be made publicly available on the Metabolomics Workbench repository.
